What's new

EMEA-003439-PIP02-23

EMEA-003439-PIP02-23

Jun 10, 2025 - 16:25
 0
EMEA-003439-PIP02-23
EMEA-003439-PIP02-23
Read More

Tags:

Previous Article

PSUSA/00010988/202410

Next Article

Human medicines European public assessment report (EPAR): Rozlytrek, entrectinib...

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Dupixent, dupilumab, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Dermatology, PIP number: P/0120/2022

Opinion/decision on a Paediatric investigation plan (PI...

May 20, 2025  0

Human medicines European public assessment report (EPAR): Sugammadex Mylan, sugammadex, Date of authorisation: 15/11/2021, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 11, 2025  0

Human medicines European public assessment report (EPAR): Viread, tenofovir disoproxil, Date of authorisation: 04/02/2002, Revision: 60, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 13, 2025  0